期刊文献+

宫颈癌规范治疗临床进展 被引量:5

Clinical progress of the standard treatment of cervical cancer
原文传递
导出
摘要 近年来随着治疗日趋规范,宫颈癌治疗疗效总体逐步提高,但对于局部晚期和复发、转移宫颈癌的治疗还有待进一步完善.早期宫颈癌根治性手术和根治性放疗疗效相当,中晚期宫颈癌同期放化疗是标准治疗,复发和转移宫颈癌使用抗血管生成治疗联合化疗能改善生存提高疗效,是否需要新辅助治疗有待进一步研究. In recent years,the efficacy of cervical cancer treatment has been increasing gradually.It has got a basic consensus of the standard treatment mode for most cervical cancer,but further effort should be done to improve the treatment response of locally advanced cervical cancer and recurrent or metastatic cervical cancer.The efect of redical surgery and radiotherpy is the same to early cervical cancer.Concurrent chemoradiotherapy is the standard treatment for patients with locally advanced cervical cancer.Chemotherapy combined with antiangiogenic targeted therapy can improve the survival of patients with recurrent or metastatic cervical cancer,while whether needing new adjuvant therapy or not,it asks for further investigation.
作者 白静
出处 《国际肿瘤学杂志》 CAS 2014年第12期937-940,共4页 Journal of International Oncology
关键词 宫颈肿瘤 妇科外科手术 放射疗法 药物疗法 分子靶向治疗 Uterine cervical neoplasms Gynecologic surgical procedures Radiotherapy Drug therapy Molecular targeted therapy
  • 相关文献

参考文献1

二级参考文献26

  • 1Lai CH, Hsueh S, Chang TC, et al. Prognostic factors in pa- tients with bulky stage IB or IIA cervical carcinoma under- going neoadjuvant chemotherapy and radical hysterectomy [ J ]. Gynecol Oncol, 1997,64 ( 3 ) :456 - 462.
  • 2Giaroli A, Sananes C, Sardi JE, et al. Lymph node metasta- ses in carcinoma of the cervix uteri :response to neoadjuvant chemotherapy and its impact on survival [J]. Gynecol On- col, 1990,39( 1 ) :34 - 39.
  • 3Choi CH,Kim TJ,Lee JW,et al. Phase II study of neoadju- rant chemotherapy with mitomycinc, vincristine and cisplatin (MVC) in patients with stages I B2 - II B cervical carcino-ma [ J ]. Gynecol Oncol,2007 ; 104 ( 1 ) :64 - 69.
  • 4Benedetti Panici P, Bellati F, Pastore M, et al. An update in neoadjuvant chemotherapy in cervical cancer [ J ]. Gynecol Oncol, 2007,107 ( 1 ) :S20 - 22.
  • 5Kim DS, Moon H, Hwang YY, et al. Preoperative adjuvant chemotherapy in the treatment of cervical cancer stage Ib, IIa,and lib with bulky tumor[J]. Gynecol Oncol, 1988,29 (3) :321 -332.
  • 6Friedlander M, Kaye SB, Sullivan A, et al. Cervical carcino- ma:a drug - responsive tumor - experience with combined eisplatin, vinblastine, and bleomyein therapy [ J ]. Gynecol Oncol, 1983,16 (2) :275 - 281.
  • 7Panici PB, Scambia G, Baiocchi G, et al. Neoadjuvant chem- otherapy and radical surgery in locally advanced cervical cancer. Prognostic factors for response and survival [ J ]. Cancer, 1991,67 (2) :372 - 379.
  • 8Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin - based radiotherapy and chemotherapy for locally advanced cervical cancer[ J]. N Engl J Med, 1999,340( 15 ) : 1144 - 1153.
  • 9Benedetti -Panici P, Greggi S, Scambia G, et al. Long - term survival following neoadjuvant chemotherapy and radi- cal surgery in locally advanced cervical cancer [ J ]. Eur J Cancer, 1998,34( 3 ) :341 - 346.
  • 10Green JA, Kirwan J J, Tierney J, et al. Concomitant chemo- therapy and radiation therapy for cancer of the uterine cer-vix M]. The Cochrane Library ,2009:25 -30.

共引文献41

同被引文献74

  • 1杜忠礼,许成山,边志民,张柏林.三磷酸腺苷结合盒转运体C2基因遗传变异与TA方案新辅助化疗乳腺癌患者骨髓抑制的关联研究[J].中国肿瘤,2020,0(4):309-315. 被引量:5
  • 2杨科,何平,屈敏,苟兰琼,曾继莎.7野调强与9野调强的骨髓限量放疗对晚期宫颈癌患者骨髓抑制的影响[J].湖南师范大学学报(医学版),2020,17(2):76-78. 被引量:4
  • 3蒋丰,陈忠东.晚期宫颈癌的治疗新进展[J].医学信息(医学与计算机应用),2014,0(7):516-516. 被引量:3
  • 4梁志清,陈勇,徐惠成,李玉艳,熊光武,张巧玉,史常旭.腹腔镜广泛子宫切除术及盆腹腔淋巴结切除术23例并发症分析[J].中华妇产科杂志,2005,40(7):438-440. 被引量:51
  • 5Siegel RL, Fedewa SA, Miller KD, et al. Cancer statistics for His- panics/Latinos, 2015 [ J]. CA Cancer J Clin, 2015,65 (6) : 457- 480.
  • 6McCormack PL. Quadrivalent human papillomavirus, recombinant vaccine : a review of its use in the prevention of premalignant ano- genital lesions, cervical and anal cancers, and genital warts [ J]. Drugs,2014,74(ll) :1253-1283.
  • 7Joura EA,Kjaer SK, Wheeler CM, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadriva- lent HPV vaccine [J]. Vaccine, 2008,26 (52) : 6844-6851.
  • 8Malagon T, Drolet M, Boily MC, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta- analysis [ J] .The Lancet. Infectious diseases, 2012, 12 (10) :781- 789.
  • 9Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination : recommendations of the Advisory Committee on Immu- nization Practices ( ACIP).MMWR.Recommendations and reports : Morbidity and mortality weekly report [ J]. Recommendations and reports / Centers for Disease Control, 2014,63 ( Rr-05 ) : 1-30.
  • 10Reagan-Steiner S, Yankey D, Jeyarajah J,et al.National, Region- al, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years-United States, 2014 [J]. MMWR Morb Mortal Wkly Rep, 2015,64 (29) : 784-792.

引证文献5

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部